NuProbe and Weigao Group Form Strategic Collaboration to Develop Liquid Biopsy Panel

By All News, Strategic Collaborations

NuProbe and Weigao Group will apply NuProbe’s proprietary Blocker Displacement Amplification (BDA) technology to developing a liquid biopsy NGS panel for non-small cell lung cancer (NSCLC). The product will be compatible with the desktop NGS instruments, and the companies plan to later apply for in vitro diagnostic (IVD) registration with NMPA, China’s equivalent of FDA.

Read More

NuProbe Licensed Two Technologies from Rice University, Launched Nanopore AML multi-gene panel

By All News, Products

The first, Non-Extensible Oligonucleotides (NEO), will allow NuProbe to provide much more rapid development of customized NGS panels, with turnaround time of less than 4 weeks. The second, Linear DNA Assembly (LDA) technology, improves the effective throughput of nanopore sequencing by up to 10-fold for short DNA, such as DNA extracted from FFPE tumor tissues and cell-free DNA from peripheral blood. Concurrently, NuProbe announces the launch of its new VarMap™ Nanopore product line.

Read More

NuProbe Announces Strategic Collaboration with QIAGEN, Completes Multiple CE IVD Product Registrations

By All News, Strategic Collaborations

NuProbe and QIAGEN will collaborate to develop next-generation sequencing (NGS)-based cancer diagnostic tests for non-invasive liquid biopsy. NuProbe and QIAGEN will explore integrating their two amplicon-based enrichment and sequencing technologies: NuProbe’s proprietary Blocker Displacement Amplification (BDA) technology and QIAGEN’s Single Primer Extension (SPE) technology,

Read More

NuProbe Announces Licensing Deal with Oxford Nanopore

By All News, Strategic Collaborations

Oxford Nanopore has licensed NuProbe’s Blocker Displacement Amplification technology globally for undisclosed consideration. The technology combination offers the potential to combine Oxford Nanopore sequencing, which offers real-time, rapid turnaround, scalable sequencing of any length DNA or RNA fragments, with the NuProbe technique to enable greater detection sensitivities and quantification of somatic mutations at less than 5% allele frequency.

Read More

    Request A Quote





    X